Click the icons below to search through Pioneer’s reports and documents.
- The Legality of QALY under the ADA (200)
- Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies (338)
- Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER) (2300)
- Will New England See Lower Prices from Drug Pricing Transparency Legislation? (1620)
- Transparency in Retail Drug Prices: Easy to Obtain but Accuracy May Be Doubtful (2804)
- Are Drug Prices Driving Healthcare Cost Growth? (2715)